HBIO (Harvard Bioscience) ROCE % : -13.54% (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Harvard Bioscience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Harvard Bioscience's annualized ROCE % for the quarter that ended in Sep. 2024 was -13.54%.

Harvard Bioscience ROCE % Historical Data

The historical data trend for Harvard Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience ROCE % Chart

Harvard Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-0.07

-1.79

1.03

-5.12

0.89

Harvard Bioscience Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															1.09	-1.09	-13.68	-9.47	-13.54

Harvard Bioscience ROCE % Calculation

Harvard Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1.035	/	( ( (145.36 - 23.249)	+	(137.366 - 26.542) )	/ 2 )
	=	1.035	/	( (122.111	+	110.824)	/ 2 )
	=	1.035	/	116.4675
	=	0.89 %

Harvard Bioscience's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-14.54	/	( ( (128.912 - 22.621)	+	(131.239 - 22.751) )	/ 2 )
	=	-14.54	/	( ( 106.291	+	108.488 )	/ 2 )
	=	-14.54	/	107.3895
	=	-13.54 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Harvard Bioscience (NAS:HBIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Harvard Bioscience ROCE % Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (NAS:HBIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

84 October Hill Road, Holliston, MA, USA, 01746

Website

https://www.harvardbioscience.com

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Executives

James W Green	director, officer: Chief Executive Officer	12525 CHADRON AVENUE, HAWTHORNE CA 90250
Alan I Edrick	director	20200 SUNBURST STREET, CHATSWORTH CA 91311
Jennifer Cote	officer: Interim CFO	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Bertrand Loy	director	C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821
Thomas W Loewald	director	81 WYMAN STREET, WALTHAM MA 02451
John F Kennedy	director	C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Susan M. Steele	director	C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103
Kenneth Fletcher Olson	officer: Chief Operating Officer	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Michael A. Rossi	officer: Chief Financial Officer	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Yash Singh	officer: Executive Vice President	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Jeffrey Duchemin	officer: Chief Executive Officer	14 EASTLAND TERRACE, HAVERHILL MA 01830
Kamalam Unninayar	officer: Chief Financial Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Robert E. Gagnon	officer: Chief Financial Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
George Uveges	director	C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464